Alzheimer's disease

被引:2468
作者
Ballard, Clive [1 ]
Gauthier, Serge [2 ]
Corbett, Anne [3 ]
Brayne, Carol [4 ]
Aarsland, Dag [5 ]
Jones, Emma [1 ]
机构
[1] Kings Coll London, Wolfson Ctr Age Related Dis, London SE1 1UL, England
[2] Douglas Mental Hlth Res Inst, McGill Ctr Studies Aging, Montreal, PQ, Canada
[3] Alzheimers Soc, London, England
[4] Univ Cambridge, Cambridge, England
[5] Univ Hosp Stavanger, Stavanger, Norway
关键词
TARGETING A-BETA; AMYLOID-BETA; COGNITIVE DECLINE; RISK-FACTOR; INCIDENT DEMENTIA; CONTROLLED-TRIAL; GENETIC-LINKAGE; CSF BIOMARKERS; BLOOD-PRESSURE; DOWN-SYNDROME;
D O I
10.1016/S0140-6736(10)61349-9
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
An estimated 24 million people worldwide have dementia, the majority of whom are thought to have Alzheimer's disease. Thus, Alzheimer's disease represents a major public health concern and has been identified as a research priority. Although there are licensed treatments that can alleviate symptoms of Alzheimer's disease, there is a pressing need to improve our understanding of pathogenesis to enable development of disease-modifying treatments. Methods for improving diagnosis are also moving forward, but a better consensus is needed for development of a panel of biological aneuroimaging biomarkers that support clinical diagnosis. There is now strong evidence of potential risk and protective factors for Alzheimer's disease, dementia, and cognitive decline, but further work is needed to understand these better and to establish whether interventions can substantially lower these risks. In this Seminar, we provide an overview of recent evidence regarding the epidemiology, pathogenesis, diagnosis, and treatment of Alzheimer's disease, and discuss potential ways to reduce the risk of developing the disease.
引用
收藏
页码:1019 / 1031
页数:13
相关论文
共 131 条
[1]
Alzhemed: A potential treatment for Alzheimer's disease [J].
Aisen, Paul S. ;
Gauthier, Serge ;
Vellas, Bruno ;
Briand, Richard ;
Saurnier, Daniel ;
Laurin, Julie ;
Garceau, Denis .
CURRENT ALZHEIMER RESEARCH, 2007, 4 (04) :473-478
[2]
[Anonymous], 2010, Lancet Neurol, V9, P643, DOI 10.1016/S1474-4422(10)70145-9
[3]
[Anonymous], 2009, COCHRANE DATABASE SY
[4]
[Anonymous], 2009, COCHRANE DATABASE SY
[5]
Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-analysis [J].
Anstey, Kaarin J. ;
Lipnicki, Darren M. ;
Low, Lee-Fay .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 16 (05) :343-354
[6]
Alcohol Consumption as a Risk Factor for Dementia and Cognitive Decline: Meta-Analysis of Prospective Studies [J].
Anstey, Kaarin J. ;
Mack, Holly A. ;
Cherbuin, Nicolas .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2009, 17 (07) :542-555
[7]
Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities [J].
Ballard, C ;
Powell, I ;
James, I ;
Reichelt, K ;
Myint, P ;
Potkins, D ;
Bannister, C ;
Lana, M ;
Howard, R ;
O'Brien, J ;
Swann, A ;
Robinson, D ;
Shrimanker, J ;
Barber, R .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2002, 17 (02) :140-145
[8]
Ballard C., 2005, DEMENTIA, P24
[9]
Neuroleptic drugs in dementia: benefits and harm [J].
Ballard, Clive ;
Howard, Robert .
NATURE REVIEWS NEUROSCIENCE, 2006, 7 (06) :492-500
[10]
The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial [J].
Ballard, Clive ;
Hanney, Maria Luisa ;
Theodoulou, Megan ;
Douglas, Simon ;
McShane, Rupert ;
Kossakowski, Katja ;
Gill, Randeep ;
Juszczak, Edmund ;
Yu, Ly-Mee ;
Jacoby, Robin .
LANCET NEUROLOGY, 2009, 8 (02) :151-157